Rakuten Investment Management Inc. boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 9.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 348,133 shares of the company’s stock after acquiring an additional 31,074 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Kenvue were worth $6,235,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of KVUE. Callan Family Office LLC purchased a new stake in Kenvue in the 2nd quarter valued at about $835,000. Calamos Advisors LLC increased its holdings in shares of Kenvue by 24.1% in the 1st quarter. Calamos Advisors LLC now owns 3,351,000 shares of the company’s stock valued at $57,771,000 after acquiring an additional 651,000 shares during the period. Pentwater Capital Management LP purchased a new position in Kenvue in the second quarter valued at about $977,094,000. Nuance Investments LLC bought a new position in shares of Kenvue during the 2nd quarter worth approximately $27,681,000. Finally, Quantinno Capital Management LP lifted its position in Kenvue by 59.5% during the first quarter. Quantinno Capital Management LP now owns 1,345,956 shares of the company’s stock valued at $23,204,000 after acquiring an additional 502,024 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group upped their price target on Kenvue from $19.00 to $20.00 and gave the stock a “neutral” rating in a research report on Monday. HSBC decreased their price objective on Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Finally, Barclays increased their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Ten research analysts have rated the stock with a Hold rating. According to data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average target price of $19.29.
Check Out Our Latest Stock Analysis on KVUE
Kenvue Stock Performance
KVUE opened at $19.31 on Friday. Kenvue Inc. has a 52-week low of $14.06 and a 52-week high of $20.13. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The company has a market cap of $37.09 billion, a P/E ratio of 21.94, a price-to-earnings-growth ratio of 1.77 and a beta of 0.48. The firm’s 50-day moving average price is $18.41 and its 200-day moving average price is $18.23.
Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $0.29 EPS for the quarter, meeting the consensus estimate of $0.29. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.86 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. Kenvue’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the firm posted $0.28 EPS. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were paid a dividend of $0.21 per share. The ex-dividend date was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue’s dividend payout ratio is presently 95.45%.
Kenvue Company Profile
Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.
The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.
Read More
- Five stocks we like better than Kenvue
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
